# Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

Study · id `cardio:ct-nct06126380` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06126380](<https://clinicaltrials.gov/study/NCT06126380>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06126380

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 132 participants.

## Technical summary

Registry record NCT06126380. Non-randomized; no masking; primary purpose treatment. Start 2023-10-25 (actual); primary completion 2029-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 132 participants (planned count; ClinicalTrials.gov record NCT06126380, source copy `cardio:ctgov-nct06126380-2025-12-10`, retrieved 2026-10-26)
- Started: 2023-10-25 (actual) (ClinicalTrials.gov record NCT06126380, source copy `cardio:ctgov-nct06126380-2025-12-10`, retrieved 2026-10-26)
- Primary completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT06126380, source copy `cardio:ctgov-nct06126380-2025-12-10`, retrieved 2026-10-26)
- Completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT06126380, source copy `cardio:ctgov-nct06126380-2025-12-10`, retrieved 2026-10-26)
- Countries: United States; Australia; Brazil; Canada; France; Germany; Spain; United Kingdom (ClinicalTrials.gov record NCT06126380, source copy `cardio:ctgov-nct06126380-2025-12-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06126380-2025-12-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
- Condition: Kidney Transplant Rejection
- Intervention (Drug): AT-1501
- Intervention (Drug): Tacrolimus
- Lead sponsor: Eledon Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Eledon Pharmaceuticals (`cardio:org-eledon-pharmaceuticals`)

## Provenance

Content hash: 6ac94a61b7dd0a256e3057fb5e7dfe8e9987ab9b0bdb785de2f9eacfc0d97888
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
